🇺🇸 FDA
Pipeline program

Dexmedetomidine Hcl 100 Mcg/mL Inj

LB.02.01/Vll/011/KEP011/2022

Phase 3 small_molecule completed

Quick answer

Dexmedetomidine Hcl 100 Mcg/mL Inj for Congenital Heart Disease in Children is a Phase 3 program (small_molecule) at Hospital Authority, Hong Kong with 1 ClinicalTrials.gov record(s).

Program details

Company
Hospital Authority, Hong Kong
Indication
Congenital Heart Disease in Children
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials